Incyte Corp.
NASDAQ:INCY 3:59:58 PM EDT
| Market Cap (Intraday) | 18.94B |
| Current PE | 39.59 |
| Forward PE | 42.64 |
| 2yr Forward PE | 24.06 |
| 10-Day MA | $84.89 |
| 50-Day MA | $83.62 |
| 200-Day MA | $85.34 |
Incyte Corp. Stock, NASDAQ:INCY
1801 Augustine Cut-Off, 1801 Augustine Cut-Off, Wilmington, Delaware 19803
United States of America
Phone: +1.302.498.6700
Number of Employees: 1773
Description
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.